The healthcare system in New Hampshire has been wrestling with a surge in cases of the Respiratory Syncytial Virus (RSV) among young children recently. However, with the introduction of new vaccines, healthcare personnel and state officials are optimistic about the forthcoming cold-weather virus season. Underscoring this optimism, Patricia Tilley, director of New Hampshire’s Division of Public Health Services, notes the unprecedented availability of potent vaccines for all major fall and winter respiratory illnesses, including COVID-19, flu, and RSV.
RSV, circulating annually every fall, typically results in mild cold symptoms in most individuals. However, it proves to be considerably hazardous for infants and the elderly, being a leading cause of infant hospitalizations in the U.S. Fortunately, the approval of the first RSV vaccines for individuals over 60 is a significant step forward. Furthermore, expectant mothers can receive the vaccine between their 32nd and 36th pregnancy weeks, offering their children protection against RSV.
The medical advancements continue with the development of a new monoclonal antibody treatment for infants up to 8 months and children up to 19 months who are at a higher risk of severe disease. This treatment works through ‘passive immunization’, supplying virus-fighting antibodies directly instead of prompting the body to generate its own, as per the mechanism of traditional vaccines.
Martha Wassell, the Director of Infection Prevention at Wentworth-Douglass Hospital in Dover, emphasizes the potential impact of these immunizations. Although older children usually possess some immunity from past exposures to the virus, newborns stand to benefit vastly from the new vaccines. She iterates that these advancements have made RSV a preventable disease, urging parents to discuss these options with their physicians.
Dr. Michael McLeod, the Associate Chief Clinical Officer for Concord Hospital Primary Care, outlines the importance of these vaccines for the elderly. RSV claims estimated lives between 6,000 to 10,000 in adults older than 65 annually. Thus, the preventive vaccine could serve as a crucial tool against RSV-induced illness. McLeod endorses the CDC’s recommendation for people over 60 to consult with medical professionals about receiving the RSV vaccine, considering their health conditions and other relevant factors.
Notably, major insurance players such as Aetna, Harvard Pilgrim, and UnitedHealthcare have confirmed that they are fully covering RSV vaccines and antibody treatments as preventive care, with New Hampshire Medicaid also extending coverage. Several state pharmacies are now in a position to offer these vaccines.
As per State Epidemiologist Dr. Benjamin Chan, albeit the national RSV activity remains low, it’s gradually showing an upward trend, marking the onset of the typical RSV infection season around October. Thus, Wassell urges those eligible to immediately consult with their healthcare providers to assess whether getting vaccinated is an appropriate measure. In light of the arrival of the viral respiratory season, it’s vital that no eligible individuals delay their vaccination.